BioNTech (BNTX) Q2 2024 earnings summary

Executive summary

• Achieved significant progress in late-stage oncology pipeline, including positive Phase 2 data for BNT111 in melanoma and advancement of multiple mRNA cancer vaccine and immunomodulator programs.

• Launched updated COVID-19 vaccines in the EU, received UK approval, and initiated U.S. regulatory filings for new variants, with JN.1-adapted vaccine first-to-market in the EU and KP.2-adapted vaccine pending U.S. approval.

• Expanded manufacturing capabilities, including CEPI partnership for Africa, new pilot facility in Mainz, and AI-driven improvements.

• Expanded strategic partnerships with CEPI, Pfizer, Regeneron, Biotheus, and DualityBio.

• Ended Q2 2024 with €18.5B in cash, cash equivalents, and security investments, bolstered by a payment from Pfizer.

Financial highlights

• Q2 2024 revenues were €128.7M, down from €167.7M in Q2 2023; H1 2024 revenues were €316.3M, down from €1,444.7M in H1 2023.

• Net loss for Q2 2024 was €807.8M (loss per share €3.36), compared to a €190.4M loss in Q2 2023.

• R&D expenses in Q2 2024 were €584.6M, up from €373.4M year-over-year, with about 90% invested in non-COVID-19 activities.

• SG&A expenses in Q2 2024 were €183.8M, up from €137.9M in Q2 2023, mainly due to IT and headcount growth.

• Cash and equivalents plus security investments at June 30, 2024: €18.5B.

Outlook and guidance

• Reiterated 2024 revenue guidance of €2.5B–€3.1B, with most revenue expected in Q4 following U.S. approval of the KP.2-adapted COVID-19 vaccine.

• Expects a full-year loss for 2024, with R&D expenses of €2.4–2.6B and SG&A of €700–800M, both expected to rise in H2.

• Guidance excludes undisclosed M&A, collaborations, or legal settlements.

• Revenue guidance reflects regulatory approvals, vaccine uptake, price levels, and pandemic preparedness contracts.